This technology identifies the LINC complex as a therapeutic target for glioblastoma to suppress tumor progression and prevent the emergence of a therapy-resistant mesenchymal state.
Glioblastoma is the most common and aggressive brain tumor, with a poor prognosis and inevitable recurrence. Although surgery, radiation, and chemotherapy remain the standard of care, diffuse tumor infiltration limits complete surgical removal, and a subset of glioblastoma cells can enter a treatment-resistant, stem-cell-like state that acts as a reserve pool for cancer proliferation following treatment. As a result, there is a critical need for novel therapeutic strategies that specifically target the mechanisms underlying glioblastoma progression and therapy resistance.
This technology identifies the LINC complex as a novel therapeutic target for glioblastoma. Nesprin-2, a component of the LINC complex that connects the nucleus to the cytoskeleton, is critical for glioblastoma cell migration and proliferation. Unlike most normal brain cells, which predominantly express nesprin-1, glioblastoma cells rely on nesprin-2, creating a tumor-specific therapeutic vulnerability. RNA interference targeting nesprin-2 reduces tumor growth size and proliferation while suppressing the therapy-resistant, stem-cell-like state that drives disease recurrence.
This technology has been validated with human glioblastoma patient samples in vitro and with mouse models in vivo.
Patent Pending
IR CU26167
Licensing Contact: Jerry Kokoshka